Study guide

8.3 Naloxone Access & Opioid Antagonists

Illinois MPJE Pharmacy Jurisprudence

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Illinois MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy

2 Chapter 2: Federal Controlled Substances Foundations

2.1 CSA Schedules I–V & Illinois Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss

3 Chapter 3: Federal Drug Regulation, Privacy & Supply Chain

3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity

4 Chapter 4: IDFPR, Licensure & Eligibility

4.1 IDFPR Authority & Sources of Illinois Pharmacy Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & Experiential Requirements

5 Chapter 5: Renewal, CE, PIC & Discipline

5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 Impaired Practitioners & Mandatory Reporting

6 Chapter 6: Technicians, Interns & Supervision

6.1 Technician Registration, Training & Certification 6.2 Supervision, Scope & No Fixed Tech Ratio 6.3 Intern Scope, Delegation & Final Verification

7 Chapter 7: Prescription Authority & Validity

7.1 Who May Prescribe in Illinois 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (720 ILCS 570 + Federal) 7.4 Refills, Partial Fills & E-Prescribing Mandate

8 Chapter 8: Advanced IL Pharmacist Practice

8.1 Collaborative Practice Agreements & Clinical Services 8.2 Immunizations & Vaccine Administration 8.3 Naloxone Access & Opioid Antagonists 8.4 Drug Administration & Therapy Management

9 Chapter 9: Counseling, DUR & Patient Safety

9.1 Patient Counseling Requirements 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs

10 Chapter 10: ILPMP & Opioid Public-Health Laws

10.1 Illinois PMP Overview, Reporting & Access 10.2 Mandatory Queries, Designees & Documentation 10.3 Legitimate Medical Purpose & Red Flags

11 Chapter 11: Dispensing: Transfers, Labels & Substitution

11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine

12 Chapter 12: Pharmacy Operations & Facilities

12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Automated Systems & Self-Service Kiosks 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Delivery & Remote Services

13 Chapter 13: Compounding & Hazardous Drugs

13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Illinois Compounding Rules & Beyond-Use Dates

14 Chapter 14: Test-Day Strategy & Final Review

14.1 When Illinois Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps

8.3 Naloxone Access & Opioid Antagonists

Key Takeaways Explain This Topic AI

225 ILCS 85/19.1 directs licensed pharmacists to dispense opioid antagonists in accordance with written, standardized procedures or protocols developed by IDFPR with IDPH and IDHS, filed at the pharmacy before implementation.

Illinois’s public-health model uses statewide/IDPH standing-order and standardized-procedure frameworks so pharmacies can furnish naloxone (and other covered opioid overdose reversal agents such as nalmefene where included) without a patient-specific individual prescription.

Before dispensing an opioid, a pharmacist shall inform patients that opioids are addictive and offer to dispense an opioid antagonist (225 ILCS 85/19.1(c)).

“Opioid antagonist” means a drug that binds opioid receptors and blocks/inhibits opioid effects, including naloxone hydrochloride or any similarly acting and equally safe FDA-approved overdose-treatment drug.

Exam intent is harm reduction and access: counsel on overdose recognition and response; do not invent barriers such as “documented OUD only” or “healthcare providers only.”

Last updated: August 2026

8.3 Naloxone Access & Opioid Antagonists

Quick Answer: Under 225 ILCS 85/19.1 , a licensed pharmacist shall dispense an opioid antagonist in accordance with written, standardized procedures or protocols developed by the Department ( IDFPR ) with IDPH and IDHS , filed at the pharmacy before implementation and available to the Department on request. Illinois operationalizes access through the IDPH statewide opioid overdose reversal agent standing order and standardized procedure so pharmacies/pharmacists can furnish naloxone (and other covered agents such as nalmefene where the order includes them) without a patient-specific individual prescription . Before dispensing an opioid , the pharmacist shall inform patients that opioids are addictive and offer to dispense an opioid antagonist . Counsel on overdose recognition and response .

This section is pure public-health quality/safety (NABP Area 2.5 -style thinking) plus therapy-access law. The General Assembly’s findings in 19.1 matter: rising opioid deaths + existence of a reversing antagonist → greater access for populations at risk.

  • Statutory Core: 225 ILCS 85/19.1
  • Legislative policy (exam “why”)

Section 19.1 opens with the policy that Illinois must expand access to opioid antagonists to avoid preventable deaths. On vignettes, answers that restrict access to “only patients with a formal OUD diagnosis,” “only first responders,” or “only with a new individual Rx every time” usually fight the statute’s purpose—unless another law truly imposes that limit (it does not for compliant standing-order dispensing).

Dispensing duty under standardized procedures

19.1(b) states that, notwithstanding contrary general or special law, a licensed pharmacist shall dispense an opioid antagonist in accordance with written, standardized procedures or protocols developed by IDFPR with IDPH and IDHS , which must be:

  • Filed at the pharmacy before implementation , and
  • Available to the Department upon request

Practice implication: Participation is not a casual drawer of samples with no procedure. The pharmacy must have the standardized procedure/protocol framework in place. The statewide standing order and Illinois Naloxone/Opioid Overdose Reversal Agent Standardized Procedure implement this public-health architecture.

Offer-when-dispensing-opioids rule

19.1(c) is highly testable:

Before dispensing an opioid , a pharmacist shall inform patients that opioids are addictive and offer to dispense an opioid antagonist .

Translate to behavior:

  • Opioid fill is happening →
  • Counsel on addiction risk (as the statute frames the warning) →
  • Offer antagonist co-dispensing / access

Failing to offer is not “optional customer service”—it is a statutory counseling/access step attached to opioid dispensing.

Definition of opioid antagonist

19.1(d): “ Opioid antagonist ” means a drug that binds to opioid receptors and blocks or inhibits the effect of opioids acting on those receptors, including but not limited to naloxone hydrochloride or any other similarly acting and equally safe drug approved by the FDA for treatment of drug overdose.

MPJE use:

Naloxone is the classic example

Newer agents (e.g., nalmefene when FDA-approved for overdose and included in the Illinois standing order/procedure updates) can fall within the similarly acting concept

  • Do not invent that only one brand name is lawful forever
  • Statewide / IDPH Standing Order & Pharmacy Participation

Illinois Department of Public Health materials describe a statewide standing order authorizing eligible naloxone entities —including pharmacies and pharmacists licensed under the Pharmacy Practice Act—to obtain and/or distribute opioid overdose reversal agents (and related kit components as the order allows) to persons who may assist someone experiencing opioid-related overdose.

Who can receive / who can be served

Public-health framing includes:

  • Persons at risk of overdose
  • Family, friends, and others who may assist
  • Not limited to “the patient who holds an OUD specialty clinic card”
  • Pharmacy participation expectations (exam-level)

Participating pharmacies/pharmacists typically must:

  • Hold lawful Illinois pharmacy/pharmacist licensure under 225 ILCS 85
  • Have knowledge of / follow the Illinois standardized procedure for opioid overdose reversal agents

Complete training that meets Act/procedure criteria (overdose prevention and recognition; administration techniques; importance of calling emergency services)

Report dispensing as directed— pharmacies shall report naloxone/nalmefene dispensing to the Illinois Prescription Monitoring Program (ILPMP) per IDPH procedure language

Stock and furnish product under the standing order without requiring a patient-named individual prescription when operating under the order

Non-pharmacy overdose education and naloxone distribution ( OEND ) programs have separate IDHS DOPP registration pathways; schools and libraries appear in expanded standing-order entity lists in public-health updates. For the MPJE pharmacist candidate, focus on pharmacy/pharmacist duties under 19.1 + standing order + procedure.

Counseling & Education: Recognition and Response

The standardized procedure educational content is the counseling outline exam writers expect:

Topic Patient/caregiver teaching points

Prevention Risk of opioids including heroin, fentanyl, prescription opioids; not using alone; avoid mixing with other CNS depressants when possible

Recognition Extreme sleepiness, slowed/stopped breathing, blue/gray lips or nails, pinpoint pupils, unresponsiveness

Response Call 911 ; administer antagonist per device instructions; rescue breathing/CPR as trained; stay until help arrives; may need repeat doses

  • Aftercare Antagonist is temporary; overdose can return; seek emergency care
  • Access How to obtain refills/additional units under the standing-order program

Counseling is not optional theater. Stems that show a pharmacist silently bagging naloxone with no education fail the public-health purpose and procedure expectations.

Relationship to Ordinary Prescriptions & Controlled Substances

Important distinctions:

Dispensing naloxone under standing order is an access pathway , not a statement that naloxone is a free-for-all controlled substance without records

Reporting to ILPMP for antagonist dispensing (as procedure requires) is separate from “you may only give naloxone if the patient is already in the PMP as an opioid patient”

Corresponding responsibility for opioid analgesic prescriptions still applies (later PMP/red-flag chapters)—naloxone access complements safe opioid dispensing; it does not replace legitimate medical purpose analysis

  • Offer antagonist when dispensing opioids applies even when the opioid Rx is legitimate
  • Public-Health Policy Intent on the Exam

When two answers both sound “careful,” pick the one that matches access + education + protocol :

  • Favored themes
  • Standing order / standardized procedure dispensing without individual Rx
  • Offer antagonist with opioid dispensing
  • Train laypersons and caregivers
  • Reduce fatal overdose
  • Disfavored themes
  • “Only physicians may ever provide naloxone”
  • “Pharmacist needs a new patient-specific Rx every time” under the standing-order model
  • “Refuse all requests from family members”
  • “No counseling needed because it is OTC-ish in practice”
  • Exam Scenarios

Scenario A — Family member. A parent requests naloxone for a household member at risk. Pharmacy participates under the statewide standing order and standardized procedure. Dispense per procedure with education —not “come back with a specialty clinic Rx only.”

Scenario B — Opioid analgesic fill. Pharmacist dispenses oxycodone, never mentions addiction risk or offers antagonist. Violates 19.1(c) offer/inform step.

Scenario C — No protocol on file. Pharmacy “sometimes sells naloxone when corporate emails a coupon” but never files standardized procedures. Fails “filed at the pharmacy before implementation” structure.

Scenario D — Definition. Item asks whether only naloxone hydrochloride qualifies. Correct approach: statute’s including but not limited to + similarly acting FDA-approved overdose drugs (and current standing-order product list).

  • Common Traps
  • Requiring individual Rx despite standing-order pathway
  • Restricting to patients with documented OUD diagnosis only
  • Skipping the offer when dispensing opioids
  • Forgetting multi-agency protocol development ( IDFPR + IDPH + IDHS )
  • Omitting overdose recognition/response education
  • Confusing ILPMP reporting of antagonist dispensing with a ban on access
  • Study Checklist
  • Cite 225 ILCS 85/19.1 as the Practice Act home for opioid-antagonist dispensing
  • Standardized procedures filed before implementation
  • Inform + offer when dispensing opioids
  • Define opioid antagonist broadly enough for naloxone and similar FDA-approved agents
  • Statewide/IDPH standing order = access without patient-specific Rx for participating pharmacies
  • Counsel: recognize → call 911 → administer → support breathing → stay

Section 8.4 expands remaining administration , CLIA-waived testing , and therapy management authorities.